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UV damage basics
Ultraviolet radiation (UV) is electromagnetic energy with 
wavelength between 10 and 400 nm, generally invisible to 
the human eye. it is a very common and virtually unavoidable 
environmental mutagen which is also produced by a number of 
machines, appliances and artificial light sources, even by LEDs 
in some devices. the individual received UV dose may greatly 
increase through light therapy for a number of human diseases 
and conditions, such as psoriasis, acne vulgaris, cutaneous 
t-cell leukemia, some skin cancers, etc. the ozone layer of 
the atmosphere blocks about 97-99% of the sun radiation, 
predominantly the short-wavelength UV, that is, practically 
all of the very short wavelength (<280 nm, UV-c) and the 
major part of the short-wavelength UV (280-320 nm, UV-B). 
the prevailing amount (about 95%) of solar UV radiation that 
reaches earth surface is long wavelength (UV-A, 320-400 nm).
the depth of penetration of UV into human skin is 
dependent on the wavelength of the UV. Generally, UV-B 
radiation penetrates more deeply than UV-A as the latter is 
easily absorbed by the uppermost keratinized skin layers (23, 
27). the most common reaction to chronic UV exposure is 
darkening of the skin, commonly known as tanning. UV-A 
produces immediate tanning that fades within days, while 
delayed tanning occurs 2-3 days after exposure to UV-A or 
UV-B and may last for several weeks to months. it is believed 
that UVA-induced tanning results from photooxidation of 
melanin coupled with redistribution of pigment granules, while 
UVB actually causes up-regulation of the melanin synthesis. 
UV is also infamously known to accelerate skin aging and 
promote neoplastic transformation of skin cells, causing 
basal skin cancers, squamous cancers and melanoma. this is 
directly dependent on the mutagenic capacity of UV irradiation 
but is also enhanced by the immunosuppressive properties of 
UV, and especially of UV-B (26, 38). UV wavelength is also 
related to the type of skin cancer, at least in animal models, 
with two peaks for squamous cancer around 293 and 354 nm, 
respectively, while melanoma is usually related to exposure to 
UV-B wavelengths of 290 to 320 nm (17). this may explain 
the relative increased prevalence of the squamous cancer 
occurrence when compared to melanoma.
UV causes various types of damage to living cells affecting 
both cellular DnA and proteins. Acute damage to the cell by 
prolonged or intensive UV exposure may cause irreversible 
damage to key cell components and may, therefore, bring 
about quick keratinocyte necrosis manifesting as inflammation, 
blistering and subsequent desquamation of the damaged skin 
layers. Repeated UV exposure may result in accumulation 
of unrepaired DnA damage which, ultimately, triggers the 
development of skin cancer. the incidence of skin cancers has 
increased dramatically in the past decades, raising the lifetime 
risk to be diagnosed with melanoma to about 2% for fair-
skinned individuals and to 0.08% for individuals with more 
deeply pigmented skin (15, 20).
DnA damage caused by UV usually are single-base 
alterations, crosslinking between the two strands of DnA or 
between nucleotides of the same strands (dimerization) and 
creation of reactive oxygen species (RoS). the latter may, 
in turn, cause strand breaks and DnA-protein crosslinks, 
expanding the damage further.
the type of DnA damage caused by UV is generally 
dependent on its energetic content. Dimers in DnA are usually 
produced by UV-B (28, 45). the two major photoproducts 
are cyclobutane pyrimidine dimers (cPDs, about 75% of all 
photoproducts) and (6-4) pyrimidine dimers ((6-4) PDs). the 
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latter can further undergo a UVB -dependent conversion to 
Dewar pyrimidinones, their valence isomers (40). it is believed 
that cPDs play a major role in UV-induced mutagenesis (25, 
30). Mutations known to be caused by UV (UV-signatures) 
have been found in the P53 gene of about 80% of precancerous 
skin lesions and in about 90% of squamous skin cancers (32).
contrary to the popular belief that UV-A is relatively harmless 
to the skin, it has been repeatedly shown that it has a strong 
potential for inducing mutagenic transformation, primarily by 
means of increasing oxidative stress via generation of RoS, but 
also including direct generation of dimers (21, 22, 36).
it is believed that UV-induced lesions are randomly 
distributed throughout DnA. cyclobutane pyrimidine dimers 
caused by UVB, however, have a preference to pyrimidine-
rich sequences, especially thymines in DnA (29). cytosines 
methylated at pos. 5 are also common hotspots for formation 
of cPDs (42).
UV-induced lesions in DnA, depending on the nature 
of the lesion, are efficiently recognized and repaired by the 
base excision repair (BeR) or the nucleotide excision repair 
(neR) mechanism of DnA repair. Presence of unrepaired 
DnA damage is a powerful trigger for halting the cell cycle 
until damage is repaired or, if it is deemed irreparable – for 
activating the cellular program for apoptosis. Generally, in 
order to avoid replication of damaged DnA, its structural and 
sequence integrity is assessed in several checkpoints, each 
governing a transition point in the cell cycle, and damage is 
repaired before the cell cycle could proceed further (13, 37, 48). 
it has been proposed that for some cells that are not expected to 
divide further, such as terminally differentiated cells, damage 
assessment and repair is limited to actively transcribed genes 
only (7, 8, 9, 31).
Bases of modern UV prevention and post-
irradiation options
At present, the stable approach of prevention of UV-
associated skin trouble is prevention, that is, avoidance of UV 
exposure and/or wearing protective sunscreen when expecting 
to be exposed to UV sources. For practical purposes, many 
specialists still use the scale of Fitzpatrick (16) to obtain 
crude but surprisingly accurate assessment for the amount of 
UV (solar radiation) that the particular patient may tolerate 
without significantly elevating the risk of UV photodermatitis 
and/or skin cancer. According to Fitzpatrick’s scale, the skin 
phototype consisting of fair skin, red hair and any amount 
of skin freckling (type i) is the type most sensitive to UV, 
followed by type ii (fair skin that does not tan, light hair colour, 
no freckling). Persons with types i and ii skin are generally 
advised not to expose themselves to any but minute amounts of 
solar radiation, to wear sunscreen and light-absorbing clothing 
on a daily basis and to screen regularly for precancerous skin 
lesions and skin cancer.
this approach, however, will work only if the individual 
is aware of the dangers associated with UV exposure and is 
prepared to comply with the specialists’ recommendations 
in order to avoid UV-induced damage. this may require a 
considerable amount of attention and perseverance, and, no 
less important, unwillingness to bend to fashion and/or peer 
pressure. it has been repeatedly proven that use of tanning beds 
is directly linked to an increase of the risk for melanoma and 
non-melanoma skin cancers (12, 19).
While use of indoor tanning appliances, however, is 
perfectly avoidable, exposure to solar radiation is not always 
preventable, especially with young children and adolescents. 
it has been shown that sunburns before age 18 are associated 
with at least 2-fold increase of the risk for skin cancer (1, 
3). Recently, an opportunity has emerged which may allow 
intervention after UV irradiation has already happened, 
namely, use of t4 endonuclease V (t4eV) – containing 
preparations. t4eV is a phage protein recognizing cPDs in 
DnA and catalyzing the excision of the 5’-base in the dimer 
and the subsequent introduction of a single-strand break at the 
newly created apyrimidine site (46), the number of the breaks 
approximately proportional to the number of pyrimidine 
dimers present in the DnA. DnA strand breaks are a very 
powerful recruiting signal for the repair machinery of the cell. 
therefore, t4 endonuclease V is not, strictly speaking, a repair 
enzyme but, rather, a signal and amplification protein which 
translates the relatively weak sign of structural DnA damage 
into imperative summons for action because of physical 
damage. the opportunity to decrease the risk of enduring UV-
damage after the irradiation has already happened constitutes 
a significant difference, as all classical anti-UV approaches 
are based on prevention of skin damage. After the damage has 
been done, the routine short-term treatment options are purely 
symptomatic and, in the long run, the management strategy is 
based entirely on watchful waiting.
Packaged in nanoparticles (e.g. liposomes), t4 
endonuclease V is able to penetrate through the keratinized 
skin layers and reach the living cells in the skin, where it tags 
the sites of cyclobutane dimers with strand breaks, allowing for 
more effective recognition of damage. Application of topical 
preparations containing T4eV in order to ensure its efficient 
delivery into target cells has been shown to aid in management 
of short-term as well as the long-term consequences of UV 
irradiation. it has been shown that the application of t4eV on 
irradiated skin inhibits the up-regulation of the proinflammatory 
factors il-10 and tnF-alpha (44) and may ameliorate the short-
term as well as long-term adverse consequences of UV-induced 
damage in healthy individuals as well as in patients defective 
in DnA repair capacity, such as xeroderma pigmentosum 
(14, 47). Relatively recently, a rapid and efficient method for 
production of high-grade t4 endonuclease V by heterologous 
expression in prokaryotes was developed (6).
Damage assessment – how to tell whether there is a 
problem
Usually, the damage in cellular DNA inflicted by UV 
irradiation is repaired effectively enough so as not to cause 
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significant trouble. There are, however, variations in the rate 
with which different lesions are repaired. For example, cPDs 
are usually repaired more effectively in the actively transcribed 
regions of the genome than in nontranscribed chromatin. this 
may vary among different species. Rodents are the absolute 
champion of DnA repair among mammals, as they can 
withstand doses of UV irradiation significantly higher than 
any other taxa, but this is related mainly to the fact that they 
strongly prioritize the transcription-coupled repair over global 
repair, targeting all the effectiveness of DnA repair at the 
transcribed genes and basically ignoring the DnA damage in the 
heterochromatin, a phenomenon termed as ‘rodent repairadox’ 
(18). this makes sense, as rodents are usually short-lived, 
therefore, it is not likely that their genome, proportional to the 
size of the genomes of long-lived mammals such as humans 
(≈109 bp), would accumulate enough mutations so as to launch 
neoplastic growth. (6-4) photoproducts are usually repaired 
more slowly than cPDs and their removal is usually entrusted 
to global genome repair.
Provided that UV radiation is so abundant, and that the 
mechanisms that control the resulting damage are not 100% 
leakproof, is it possible that when these and the related defense 
mechanisms fail – albeit temporarily – that malignant skin 
disease is imminent? considering that human skin cells labour 
under constant barrage of UV since birth, the average healthy 
individual seems to cope very well with UV irradiation, with 
the rare exceptions of inherited defects of DnA repair proteins 
which produce disease phenotype. in fact, it was the research 
of human disease (11) that brought about the importance of 
DnA repair as a fundamental process in living cells and added 
the DnA repair as a member in the ‘nuclear transactions’ 
triad (replication, transcription, repair). For a long time it 
was believed that defects in DnA repair are so severe that 
affected foetuses are seldom born alive. it turned out, however, 
that the readiness for repair of lesions in DnA constitutes a 
major factor in human health status and was not a constant 
throughout the life of the individual and that it may fluctuate 
depending on the age and general health of the individual and 
environmental factors. in the last decade it became clear that 
inter-individual variations in the capacity for repair of DnA 
damage in clinically healthy individuals may significantly alter 
the risk for development of various tumours, influence the 
outcome after various treatments and even modify the success 
rate of hlA-matched transplantations (2, 9, 22, 24, 33, 35). 
Also, the capacity to repair the DNA damage inflicted onto 
tumour cells by anticancer therapy may be used to assess the 
risk for acute toxicity in some patients (10, 39).
All this immediately brought about the question about 
how to measure individual repair capacity. the latter proved 
to be difficult, as the types of DNA damage are legion and, 
consequently, the living cells have developed similarly diverse 
mechanisms for recognizing and repairing them. Finally, the 
key to this problem was found in the basic assumption that 
since all types of DnA repair – eventually – end up in DnA 
synthesis, therefore, the rate of repair could be measured by 
the rate of DnA synthesis (5, 34, 43). this solution was far 
from ideal, however, as the relative amount of DnA synthesis 
due to repair is about 1-2 orders of magnitude lower than 
the replicative DnA synthesis. Moreover, large amounts of 
DnA damage could effectively block the progress through 
the cell cycle and allow the non-replicative component of 
DnA synthesis to come forward, but they could also cause 
rapid cell death without any DnA repair. on the other hand, 
small amounts of certain types of damage stimulated both 
types of DnA synthesis, which complicated things even 
further. the answer to the dosage dilemma was found in an 
agent whose replication-inhibiting properties were discovered 
long ago, namely, hydroxyurea (41). Model systems based on 
hydroxyurea blockage have been set up and tested (4, 5) but it 
was not until recently that these models have been integrated 
into the context for practical use in routine assessment and 
monitoring individual repair capacity (8). it could be expected 
that the differential synthesis blockage may become a method 
of choice for measurement of individual repair capacity, as it 
is independent of the particular type of the damage and the 
genomic region in which the damage occurs. Also, unlike other 
methods, it works in vitro (that is, with cultured cells) as well as 
in vivo, which may be a significant advantage when assessing 
repair capacity in individuals with known or suspected DnA 
repair defects, e.g. sun sensitivity (xeroderma pigmentosum), 
general sensitivity to ionizing and/or UV radiation (Ataxia 
telangiectasia, nijmegen syndrome), cancer susceptibility 
(familial melanoma, familial breast cancer, etc.).
Conclusions
As UV is a very common environmental agent, accidental 
overexposure is virtually inevitable throughout the life of the 
individual. Usually, UV-caused damage to DnA is repaired 
effectively, and a very small proportion of UV-related defects 
result in mutations with oncogenic potential inherited in a 
dividing cell’s progeny. Various strategies have been developed 
to avoid or decrease UV damage to cellular DnA, based on 
prevention of exposure as well as on post-irradiation measures. 
the capacity for DnA repair varies during the life of the 
individual and must, therefore, be periodically assessed so as to 
determine whether the individual is coping with environmental 
UV damage. Assessment of individual repair capacity might 
modify the existing therapeutic strategies for common cancers. 
Also, it is possible that the assessment of DnA repair capacity 
may become an important component for prognostication in 
human disease and, therefore, ought to become a routine part 
of health prophylaxis.
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